FDA approves omalizumab for food allergy reactions based on NIH research

Today’s Food and Drug Administration approval of a supplemental biologics license for the monoclonal antibody omalizumab (Xolair) highlights the vital role of the National Institutes of Health-supported research that underpins the FDA decision.

Astellas agrees to take over Propella Therapeutics for $175m

Share this article Astellas plans to fund the acquisition of Propella using cash on hand. Credit: JHVEPhoto / Shutterstock.com. Astellas Pharma has signed an agreement for

November 16, 2023

Senolytic drugs are not a “one-size-fits-all” remedy and may benefit some older women

Drugs that selectively kill senescent cells may benefit otherwise healthy older women but are not a “one-size-fits-all” remedy, Mayo Clinic researchers have found.

July 2, 2024

Social factors play crucial role in determining lifespan

The interplay of a quartet of sex, marital status, education, and race is linked to an 18 year lifespan gap for US citizens, and while

August 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.